Standout Papers

Donanemab in Early Alzheimer’s Disease 2021 2026 2022 2024891
  1. Donanemab in Early Alzheimer’s Disease (2021)
    Mark A. Mintun, Albert Lo et al. New England Journal of Medicine
  2. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease (2025)
    Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology

Immediate Impact

1 by Nobel laureates 16 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

Glycocalyx dysregulation impairs blood–brain barrier in ageing and disease
2025 StandoutNatureNobel
Small and long non-coding RNAs: Past, present, and future
2024 Standout
2 intermediate papers

Works of Paul Ardayfio being referenced

Donanemab in Early Alzheimer’s Disease
2021 Standout

Author Peers

Author Last Decade Papers Cites
Paul Ardayfio 342 867 372 428 31 1.6k
Ana Graf 245 923 287 509 38 1.6k
Keith M. Gregg 152 848 258 419 21 1.8k
Gary Tong 652 845 787 346 34 2.1k
Martin Tolar 200 1110 437 372 33 1.7k
Akihiko Koyama 460 1007 413 284 24 1.7k
Shinji Matsunaga 244 457 404 546 68 2.0k
Susan Abushakra 139 982 294 432 42 1.5k
B. McDonald 486 784 543 540 42 2.1k
Laëtitia Lemoine 330 853 338 407 31 1.5k
Alette M. Wessels 131 952 253 673 46 1.8k

All Works

Loading papers...

Rankless by CCL
2026